Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Besides Wall Street's top -and-bottom-line estimates for DexCom (DXCM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Stay Ahead of the Game With DexCom (DXCM) Q3 Earnings: Wall Street's Insights on Key Metrics

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=108924&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. Lawsuit - DXCM

NEW YORK CITY, NY / ACCESSWIRE / October 21, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired DexCom securities between April 28, 2023, and July 25, 2024, inclusive (the "Class Period").

FINAL DXCM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds DexCom, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=108885&wire=1 or contact Joseph E. Levi, Esq.

October 21, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against DXCM

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM DEADLINE NEWS: The October 21 Deadline in DexCom, Inc. Securities Fraud Class Action is Today; Contact BFA Law if You Lost Money (Nasdaq:DXCM)

NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=108866&wire=1 or contact Joseph E. Levi, Esq.

DexCom, Inc. Class Action: Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024 - DXCM

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline.

DXCM DEADLINE: RLF, A LEADING LAW FIRM, Encourages DexCom, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important October 21 Deadline in Securities Class Action – DXCM

NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=108851&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against DexCom, Inc. (DXCM) - October 21, 2024 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your DexCom, Inc. (NASDAQ:DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form?prid=108817&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024 - DXCM

RADNOR, PA / ACCESSWIRE / October 20, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. ("DexCom") (NASDAQ:DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the "Class Period") The lead plaintiff deadline is October 21, 2024. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered DexCom losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/dexcom-inc?utm_source=PR&utm_medium=link&utm_campaign=dxcm&mktm=r You can also contact attorney Jonathan Naji, Esq.

DXCM Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit

NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired DexCom securities between April 28, 2023, and July 25, 2024, inclusive (the "Class Period").

FINAL REMINDER DXCM DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts DexCom, Inc. Investors to Participate in the Class Action Lawsuit!

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024. DexCom describes itself as an “international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767.

RLF Urges DexCom, Inc. (NASDAQ: DXCM) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK, NY / ACCESSWIRE / October 18, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM DEADLINE UPDATE: DexCom, Inc. Investors are Alerted of Monday, October 21 Court Deadline; Contact BFA Law about Securities Fraud Class Action

RADNOR, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024.

DXCM Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit

LOS ANGELES , Oct. 18, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Class Period: January 8, 2024 – July 25, 2024 Lead Plaintiff Deadline: October 21, 2024 If you wish to serve as lead plaintiff of the DexCom lawsuit, you can submit your contact information at www.glancylaw.com/cases/DexCom-Inc/.

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESSWIRE / October 18, 2024 / If you suffered losses exceeding $100,000 in DexCom between April 28, 2023 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM) and reminds investors of the October 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024 - DXCM

Recent developments might have scared away some investors, but patience could pay off.

Where Will DexCom Be in 5 Years?

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the DexCom class action lawsuit – captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.) – charges DexCom, Inc. (NASDAQ: DXCM) and certain of DexCom's top executives with violations of the Securities Exchange Act of 1934. Subsequently filed complaints are captioned Oakland County Employees' Retirement System v. DexCom, Inc., No. 24-cv-01804 (S.D. Cal.), and Carnes v. DexCom, Inc., No. 24-cv-01809 (S.D. Cal.).

TUESDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - DXCM

NEW YORK CITY, NY / ACCESSWIRE / October 18, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired DexCom securities between April 28, 2023, and July 25, 2024, inclusive (the "Class Period").

DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important October 21 Deadline in Securities Class Action – DXCM

NEW YORK, NY / ACCESSWIRE / October 17, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM FRAUD UPDATE: DexCom, Inc. Investors have until Monday, October 21 to Contact BFA Law about the Court Deadline in Securities Fraud Class Action (Nasdaq:DXCM)

NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. - DXCM

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On July 25, 2024, after the market closed, DexCom announced its seco.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DexCom, Inc. (DXCM)

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: DexCom (DXCM) Q3 Earnings Expected to Decline

RADNOR, Pa. , Oct. 17, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. ("DexCom") (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the "Class Period") The lead plaintiff deadline is October 21, 2024.

News for DexCom Stock (DXCM)